| General Information of Drug Metabolite (DM) (ID: DM017245) |
| DM Name |
PF-04991532 metabolite M5
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Hydroxylation |
PF-04991532
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| PF-04991532 |
DR3201
|
Phase 2 |
Diabetic complication |
|
|
| References |
| 1 |
Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
